Patents Assigned to SERPENTIDE INC.
  • Long-lasting GLP1 analogue drug for type-2 diabetes
    Patent number: 12122817
    Abstract: Modified glucagon-like peptide (GLP1) fusion proteins with modified GLP1 polypeptides and related methods of use are described. Aspects of the disclosure further relate to fusion proteins that are GLP1 receptor agonists with a modified GLP1 fused to a stabilizing domain such as an extra cellular domain or antibody. Fusion proteins with modified GLP1 that are useful for treating or ameliorating a symptom or indication of a blood sugar disorder such as obesity and diabetes are also provided.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: October 22, 2024
    Assignee: SERPENTIDE INC.
    Inventor: Yang Wei